These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30146960)

  • 21. Hospital pricing policies: the simple economics.
    Robison GA; Robison HD
    Health Care Strateg Manage; 1986 Oct; 4(10):21-5. PubMed ID: 10311825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness and pricing of antibacterial drugs.
    Verhoef TI; Morris S
    Chem Biol Drug Des; 2015 Jan; 85(1):4-13. PubMed ID: 25521641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Countries mull over incentives for developing antibiotics.
    Anderson T
    Lancet; 2016 May; 387(10031):1894-5. PubMed ID: 27203638
    [No Abstract]   [Full Text] [Related]  

  • 24. Outpatient parenteral antibiotic therapy. Management of serious infections. Part I: Medical, socioeconomic, and legal issues. Reimbursement.
    Tierce JC
    Hosp Pract (Off Ed); 1993 Jun; 28 Suppl 1():44-51. PubMed ID: 8505398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preserving the 'commons': addressing the sustainable use of antibiotics through an economic lens.
    Morel CM; Edwards SE; Harbarth S
    Clin Microbiol Infect; 2017 Oct; 23(10):718-722. PubMed ID: 28811243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Policy in Latvia.
    Silins J; Szkultecka-Dębek M
    Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
    Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
    J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Reimbursement policy for ambulatory treatment of pediatric infections with ceftriaxone].
    Krahenbuhl JD; Di Paolo E; Steiner S; Gehri M
    Rev Med Suisse; 2005 Jul; 1(27):1814-5. PubMed ID: 16119297
    [No Abstract]   [Full Text] [Related]  

  • 29. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M; Mossialos E
    Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
    [No Abstract]   [Full Text] [Related]  

  • 30. Stimulating antibiotic development.
    Tillotson G
    Lancet Infect Dis; 2010 Jan; 10(1):2-3. PubMed ID: 20129141
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B; Bartlett J; Wunderink R; Gilbert DN
    Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coronary stents and the uptake of new medical devices in the German system of inpatient reimbursement.
    Henschke C; Baeumler M; Gaskins M; Busse R
    J Interv Cardiol; 2010 Dec; 23(6):546-53. PubMed ID: 20735711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An antibiotic's journey from marketing authorization to use, Norway.
    Årdal C; Blix HS; Plahte J; Røttingen JA
    Bull World Health Organ; 2017 Mar; 95(3):220-226. PubMed ID: 28250535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.
    Gress S; Niebuhr D; May U; Wasem J
    Pharmacoeconomics; 2007; 25(6):443-54. PubMed ID: 17523750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.
    Persson U; Norlin JM
    Appl Health Econ Health Policy; 2018 Apr; 16(2):157-165. PubMed ID: 29470774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economics of antibiotic resistance.
    Sipahi OR
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):523-39. PubMed ID: 18662118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paying for innovation: reimbursement incentives for antibiotics.
    Hwang TJ; Carpenter D; Kesselheim AS
    Sci Transl Med; 2015 Feb; 7(276):276fs9. PubMed ID: 25717095
    [No Abstract]   [Full Text] [Related]  

  • 38. Implementation of a Market Entry Reward within the United States.
    Daniel GW; Schneider M; Lopez MH; McClellan MB
    J Law Med Ethics; 2018 Jun; 46(1_suppl):50-58. PubMed ID: 30146957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to antibiotics: are we in the post-antibiotic era?
    Alanis AJ
    Arch Med Res; 2005; 36(6):697-705. PubMed ID: 16216651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming the current deadlock in antibiotic research.
    Schäberle TF; Hack IM
    Trends Microbiol; 2014 Apr; 22(4):165-7. PubMed ID: 24698433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.